Biopharmaceutical firms are rapidly advancing Phase 3 clinical trials testing GLP-1 analogues for Non-Alcoholic Steatohepatitis (NASH). Clinical trial data indicates substantial reduction in liver fat accumulation and systemic inflammation.
Clinical & Commercial Outlook
Regulatory bodies have granted fast-track status to three leading compounds following positive histology outcomes. If approved, these treatments could address an underserved patient demographic exceeding 115 million individuals globally, restructuring therapeutic paradigms for metabolic diseases.